Sepsis Diagnosis and Optimisation of Antimicrobials

Sepsis Diagnosis

Sepsis remains an increasingly complex disease with vastly different outcome rates globally. It can be healthcare-associated and is often multi-drug resistant. Sepsis kills over 5000 Australians each year and accounts for one in four ICU deaths.

Current diagnostic approaches are inadequate in a context where time is critical. In this webinar, leading researchers will present the latest data and interpretations from recent studies and treatment interventions including diagnostic considerations, use of steroids, combination antimicrobial therapy, and nebulised antimicrobials.

The workshop also discusses the role of optimised dosing and the latest evidence regarding antimicrobial drug monitoring in sepsis.

Learning objectives

  1. Diagnostic considerations for sepsis
  2. Role of steroids in sepsis
  3. Role of combination antimicrobial therapy in sepsis
  4. Role of nebulised antimicrobials in ventilator related pneumonia 
  5. Role of optimised antimicrobial dosing
  6. Latest evidence relating to antimicrobial drug monitoring

Optimisation of Antimicrobials

This webinar will also address the pharmacokinetic considerations in this special patient population, covering optimisation of antimicrobials for the treatment of sepsis, and the role of therapeutic drug monitoring. 

To receive updates subscribe to the CRE REDUCE mailing list by contacting


Sepsis Diagnosis and Optimisation of Antimicrobials webinar

Tue 18 May 2021 6:00pm
6.00 pm AEST Welcome and introduction
Prof Jason Roberts, The University of Queensland, Brisbane, Australia




6.05 pm  Diagnosis of sepsis in a patient colonised with MDR organisms
Professor Jan de Waele, Ghent University Hospital, Ghent, Belgium




6.25 pm  The role of PCT, CRP or other biomarkers to improve sepsis diagnosis
Associate Professor Pedro Povoa, New University of Lisbon, Lisbon, Portugal




6.45 pm  Continuous infusion or Therapeutic Drug Monitoring of Beta-Lactams?
Professor Jason Roberts, The University of Queensland, Brisbane, Australia




7.05 pm  Beta-lactam antibiotic TDM (recorded)
Associate Professor Mohammad H. Alshaer, Infectious Disease Pharmacokinetics Laboratory, University of Florida, United States of America




7.25 pm  Inhaled antibiotic therapy
Associate Professor Jayesh Dhanani, UQ Centre for Clinical Research, Brisbane, Australia




7.45 pm  When is the duration of antibiotic therapy too short for sepsis?
Associate Professor Benjamin Rogers, Monash Health and Monash University, Melbourne, Australia




8.05 pm  Treatment for intermediate resistant organisms
Professor Claire Roger, Centre Hospitalier Universitaire de Nîmes, France





Platinum sponsors:



Luminita Vlad
07 3346 5045